Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 14/20 | 0.59 |
| ▸ | RARB | P10826 | 10/20 | 0.59 |
| ▸ | RARA | P10276 | 8/20 | 0.59 |
| ▸ | RXRA | P19793 | 3/20 | 0.56 |
| ▸ | RXRB | P28702 | 2/20 | 0.55 |
| ▸ | RXRG | P48443 | 2/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.48 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8846090 | 0.89 | RARB (0.65) | RARGRARBRARARXRARXRB | |
| SCHEMBL8846040 | 0.87 | PTGER1 (0.64) | RARGRARBRARARXRARXRB | |
| SCHEMBL8846206 | 0.86 | RARG (0.47) | RARGRARBRARARXRARXRB | |
| SCHEMBL5847006 | 0.84 | RARG (0.74) | RARGRARBRARARXRA | |
| SCHEMBL8846009 | 0.83 | PTPN1 (0.50) | RARGRARBRARARXRARXRB | |
| SCHEMBL8845968 | 0.81 | CYP3A4 (0.53) | RARGRARBRARARXRARXRB | |
| SCHEMBL8846089 | 0.80 | RXRA (0.49) | RARGRARBRARARXRARXRB | |
| SCHEMBL8845921 | 0.80 | PTGER1 (0.54) | RARGRARBRARARXRARXRB | |
| SCHEMBL8676840 | 0.80 | RXRB (0.71) | RARGRARBRARARXRARXRB | |
| SCHEMBL8846492 | 0.80 | RARB (0.49) | RARGRARBRARARXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0664282-B1 | Biaryl phospholipase A2 inhibitors | BRISTOL MYERS SQUIBB CO (US) | 1997-10-22 | — | — | EP | claimed |
| EP-0664282-A1 | Biaryl phospholipase A2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-26 | — | — | EP | claimed |
| US-5391817-A | Antiinflammatory agents | BRISTOL-MYERS SQUIBB (US) | 1995-02-21 | — | — | US | claimed |
| US-8772327-B2 | Phenylpropionic acid derivative and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20130131134-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | MORITA KOHEI (JP) | 2013-05-23 | — | — | US | disclosed |
| US-8334314-B2 | Phenylpropionic acid derivative and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-12-18 | — | — | US | disclosed |
| EP-2272832-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20100093819-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-1477472-B1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-6867320-B2 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-15 | — | — | US | disclosed |
| EP-1477472-A1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-04 | — | — | US | disclosed |
| EP-0664282-B1 | Biaryl phospholipase A2 inhibitors | BRISTOL MYERS SQUIBB CO (US) | 1997-10-22 | — | — | EP | disclosed |
| EP-0664282-A1 | Biaryl phospholipase A2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-26 | — | — | EP | disclosed |
| US-5391817-A | Antiinflammatory agents | BRISTOL-MYERS SQUIBB (US) | 1995-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131134-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | PLA2G12A, PLA2G4A, PLA2G4B | RARG 2637/4885RARB 2328/4885RARA 2137/4885 |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | PTGER1, CYSLTR1, PTGS1 | RARG 1288/4885RARB 1219/4885RARA 618/4885 |
| US-20100093819-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | PLA2G12A, PLA2G4A, PLA2G4B | RARG 2637/4885RARB 2328/4885RARA 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.